BioAge Labs Inc.

BIOA12 Dec 2024
Healthcare
$4.46
+0.08 (+7.61%)
Lowest Today
$4.27
Highest Today
$4.95
Today’s Open
$4.46
Prev. Close
$4.47
52 Week High
$26.62
52 Week Low
$4.23
To Invest in BioAge Labs Inc.

BioAge Labs Inc.

Healthcare
BIOA12 Dec 2024
+0.08 (+7.61%)
1M
3M
6M
1Y
5Y
Low
$4.27
Day’s Range
High
$4.95
4.27
52 Week Low
$4.23
52-Week Range
52 Week High
$26.62
4.23
1 Day
-
1 Week
-75.44%
1 month return
-80.36%
3 month return
-76.01%
6 month return
-76.01%
1 Year return
-
3 Years return
-
5 Years return
-
10 Years return
-

Market Status

Fundamentals
Market Cap
674.12 mln
PB Ratio
0
PE Ratio
0
Enterprise Value
539.05 mln
Total Assets
25.92 mln
Volume

Fund house & investment objective

Company Information
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Organisation
BioAge Labs Inc.
Employees
56
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Kristen  Fortney Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities